Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 [J] Lancet Oncol. 2015 Jul;16(7):830-8. d...
1. Russo Alessandro,Franchina Tindara,Ricciardi Giuseppina et al. Heterogeneous Responses to Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) in Patients with Uncommon EGFR Mutations: New Insights and Future Perspectives in thi...
[1]Sabari JK,Heymach JV,Sandy B.Hitting the Right Spot:Advances in the Treatment of NSCLC With Uncommon EGFR Mutations.J Natl Compr Canc Netw.2021;19(Suppl_2):S1-S11.doi:10.6004/jnccn.2021.0200. [2]Oxnard GR,Lo PC,Nishino M,et al.Natural history and molecular characteristics of lung ...
EGFRmutations:"wrong"typedetectionisreliable? WangJie,BeijingCancerHospital,Departmentofchestoncology, SchoolofClinicalOncology,PekingUniversity ___ Intwenty-firstCenturythefieldoflungcancertherichest eventisfoundinthemilepostsignificanceofepidermalgrowth factorreceptor...
[4]Galvez C, Jacob S, Finkelman B S, et al. The role of EGFR mutations in predicting recurrence in early and locally advanced lung adenocarcinoma following definitive therapy[J]. Oncotarget, 2020, 11(21): 1953-1960. [5]Liu S Y, Bao H, Wang Q, et al. Genomic signatures define three...
Yan N, Guo S, Huang S, Zhang H and Li X (2024) The efficacy of furmonertinib in untreated advanced NSCLC patients with sensitive EGFR mutations in a real-world setting: a single institutional experience. Front. Oncol. 14:1331128. doi: 10.3389/fonc.2024.1331128...
图1 EGFR胚系突变导致肺癌的患者示意图 参考文献:Liu M, Niu X, Liu H, Chen J. Germline EGFR mutations in lung cancer (Review). Oncol Lett. 2023 May 16;26(1):282. doi: 10.3892/ol.2023.13868. PMID: 37274482; PMCID: PMC10236141.
5.Lee C K, Wu Y L, Ding P N, et al. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis[J]. Journal of Clinical Oncol...
[11] Miwa M , Okuma Y , Kashima J , et al. Survival analysis of advanced NSCLC patients harboring EGFR mutations with zoledronate or denosumab[C]// ERS International Congress 2017 abstracts. 2017. [12] Saito G , Ebata T , Ishiwata T , et al. Risk factors for skeletal-related events ...
1. Yufeng Li, Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer, Cell Communication and Signaling (2023) 21:71 2. 与爱共舞订阅号:又一个肺癌四代靶向药倒下,究竟谁能破解奥希替尼耐药?